Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
St. Clare Hospital
mi
from
Tacoma, WA
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
St. Clare Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Southwest Washington Medical Center Cancer Center
mi
from
Vancouver, WA
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Wenatchee Valley Clinic
mi
from
Wenatchee, WA
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Wenatchee Valley Clinic
mi
from
Wenatchee, WA
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
United Hospital Center
mi
from
Clarksburg, WV
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
United Hospital Center
mi
from
Clarksburg, WV
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Community Comprehensive Cancer Center at Camden-Clark Memorial Hospital
mi
from
Parkersburg, WV
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Community Comprehensive Cancer Center at Camden-Clark Memorial Hospital
mi
from
Parkersburg, WV
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Fox Valley Hematology and Oncology - East Grant Street
mi
from
Appleton, WI
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Fox Valley Hematology and Oncology - East Grant Street
mi
from
Appleton, WI
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Luther Midlelfort Hospital
mi
from
Eau Claire, WI
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Luther Midlelfort Hospital
mi
from
Eau Claire, WI
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Midelfort Clinic - Luther
mi
from
Eau Claire, WI
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Midelfort Clinic - Luther
mi
from
Eau Claire, WI
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Vince Lombardi Cancer Center - Elkhorn
mi
from
Elkhorn, WI
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Vince Lombardi Cancer Center - Elkhorn
mi
from
Elkhorn, WI
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Medical Consultants, Limited
mi
from
Milwaukee, WI
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Medical Consultants, Limited
mi
from
Milwaukee, WI
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
All Saints Cancer Center at All Saints Medical Center
mi
from
Racine, WI
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
All Saints Cancer Center at All Saints Medical Center
mi
from
Racine, WI
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
CancerCare Manitoba
mi
from
Winnipeg,
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine As First-Line Therapy Of Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
CancerCare Manitoba
mi
from
Winnipeg,
Click here to add this to my saved trials
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Status: Enrolling
Updated:  11/19/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Status: Enrolling
Updated: 11/19/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Status: Enrolling
Updated:  11/19/2015
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer
Status: Enrolling
Updated: 11/19/2015
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
Pharmacological Ascorbate for the Control of Metastatic and Node-Positive Pancreatic Cancer (PACMAN): A Phase II Trial
Status: Enrolling
Updated:  11/30/2015
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
Pharmacological Ascorbate for the Control of Metastatic and Node-Positive Pancreatic Cancer (PACMAN): A Phase II Trial
Status: Enrolling
Updated: 11/30/2015
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer
EMUNE-07 Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer
Status: Enrolling
Updated:  12/18/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer
EMUNE-07 Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer
Status: Enrolling
Updated: 12/18/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Prospective Randomized, Double Blind, Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Status: Enrolling
Updated:  12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Prospective Randomized, Double Blind, Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Status: Enrolling
Updated: 12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Spectroscopy With Surface Coils and Decoupling
Spectroscopy With Surface Coils and Decoupling
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma
Status: Enrolling
Updated:  12/23/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma
Status: Enrolling
Updated: 12/23/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Status: Enrolling
Updated:  1/8/2016
National Cacner Institue
mi
from
Bethesda, MD
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Status: Enrolling
Updated: 1/8/2016
National Cacner Institue
mi
from
Bethesda, MD
Click here to add this to my saved trials
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
Status: Enrolling
Updated:  1/11/2016
Mayo Clinic
mi
from
Jacksonville, FL
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer
Status: Enrolling
Updated: 1/11/2016
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
Cancer Center at Presbyterian Hospital
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
University of New Mexico Cancer Center @ Lovelace Medical Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/15/2016
Memorial Medical Center- Cancer Center
mi
from
Las Cruces, NM
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
INST 0802: Phase II Trial of Combination Irinotecan, Oxaliplatin and Cetuximab for Patients With Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/15/2016
Memorial Medical Center- Cancer Center
mi
from
Las Cruces, NM
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated:  1/15/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated: 1/15/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated:  1/15/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated: 1/15/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated:  1/15/2016
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer
Phase I Dose Escalation and Pharmacokinetics Study of the Radiosensitizer, Gadolinium Texaphyrin (Gd-Tex, NSC 695238) With Concurrent Radiotherapy in Advanced Biliary Tree and Pancreatic Cancers
Status: Enrolling
Updated: 1/15/2016
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer
Phase I Dose Escalation Trial of a 100 aa Synthetic Mucin Peptide Admixed With SB-AS2 as Adjuvant in Locally Advanced and Resected Pancreatic Cancer
Status: Enrolling
Updated:  1/19/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer
Phase I Dose Escalation Trial of a 100 aa Synthetic Mucin Peptide Admixed With SB-AS2 as Adjuvant in Locally Advanced and Resected Pancreatic Cancer
Status: Enrolling
Updated: 1/19/2016
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/21/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 1/21/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Status: Enrolling
Updated:  1/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Status: Enrolling
Updated: 1/22/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  1/24/2016
Massachusetts General Hospital Dept. of Mass General Hospital
mi
from
Boston, MA
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 1/24/2016
Massachusetts General Hospital Dept. of Mass General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  1/24/2016
Memorial Sloan Kettering Cancer Center MSKCC SC
mi
from
New York, NY
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 1/24/2016
Memorial Sloan Kettering Cancer Center MSKCC SC
mi
from
New York, NY
Click here to add this to my saved trials
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  1/24/2016
University of Utah / Huntsman Cancer Institute Huntsman UT
mi
from
Salt Lake City, UT
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 1/24/2016
University of Utah / Huntsman Cancer Institute Huntsman UT
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  1/24/2016
Novartis Investigative Site
mi
from
Barcelona,
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
A Phase Ib, Open-label, Multicenter, Dose-escalation, Safety and Tolerability Study of LDE225 in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 1/24/2016
Novartis Investigative Site
mi
from
Barcelona,
Click here to add this to my saved trials
Clinical Outcomes in Hereditary Cancer
Clinical Outcomes in Hereditary Cancer
Status: Enrolling
Updated:  1/27/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Clinical Outcomes in Hereditary Cancer
Clinical Outcomes in Hereditary Cancer
Status: Enrolling
Updated: 1/27/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
A Randomized Multi-center Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated:  2/19/2016
Columbia University Medical Center
mi
from
New York, NY
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
A Randomized Multi-center Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated: 2/19/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
A Randomized Multi-center Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated:  2/19/2016
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
A Randomized Multi-center Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Status: Enrolling
Updated: 2/19/2016
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
Phase I Study of Gemcitabine With Novel RAF Kinase-Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (BAY 43-9006) and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  2/26/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
Phase I Study of Gemcitabine With Novel RAF Kinase-Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (BAY 43-9006) and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 2/26/2016
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Multiple Dose Administration in Healthy Subjects
Status: Enrolling
Updated:  2/29/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Vitamin E δ-Tocotrienol Multiple Dose in Healthy Subjects
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Vitamin E δ-Tocotrienol Following Multiple Dose Administration in Healthy Subjects
Status: Enrolling
Updated: 2/29/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer
Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients: A Prospective Pilot Study
Status: Enrolling
Updated:  2/29/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer
Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients: A Prospective Pilot Study
Status: Enrolling
Updated: 2/29/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
Pharmacodynamic Study of Fibroblast Activity Protein in Patients With Localized Pancreas Cancer Undergoing Surgical Resection
Status: Enrolling
Updated:  3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
Pharmacodynamic Study of Fibroblast Activity Protein in Patients With Localized Pancreas Cancer Undergoing Surgical Resection
Status: Enrolling
Updated: 3/1/2016
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Howard University Cancer Center
mi
from
Washington,
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Howard University Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Medical College of Georgia Cancer Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated:  3/1/2016
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County
mi
from
Mount Holly, NJ
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Comparing the Lozenge to the Patch for Smoking Cessation
Status: Enrolling
Updated: 3/1/2016
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Burlington County
mi
from
Mount Holly, NJ
Click here to add this to my saved trials